Research
Hormonal
SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Ipragliflozin) improve liver fat content and liver enzymes in patients with Type 2 Diabetes and NAFLD, with some evidence of improving liver fibrosis.
If you have Type 2 Diabetes and NAFLD, SGLT2 inhibitors like Empagliflozin or Dapagliflozin may help reduce liver fat and improve liver enzymes. Discuss these options with your doctor, especially if you are already managing your blood sugar with other medications.
GoodSupportsHIGH confidence
SGLT2i could improve steatosis and fibrosis in patients with T2DM... meta-analysis... indicated that drug therapy with SGLT2i could improve LFC, liver enzyme levels, BMI, inflammatory markers, etc. in Asian T2DM patients with NAFLD
Why this rating
Supported by multiple randomized controlled trials and meta-analyses.
Source
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2022.1087260
narrative_reviewCited 283×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions, specifically caloric restriction and exercise, are the foundational first-line treatment for NAFLD, capable of inducing 5-10% weight loss and improving insulin resistance and hepatic steatosis.Good
- GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide) significantly reduce liver fat content and improve liver enzymes in patients with Type 2 Diabetes and NAFLD, with Semaglutide showing histological resolution of NASH in Phase II trials.Good
- Bariatric surgery is an effective treatment for severe obesity in adolescents and adults with NAFLD, significantly improving liver histology, fibrosis, and metabolic parameters, but carries risks of complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →